Physician

Alonso Pacheco, MD

According to 2025 Medicare claims, Alonso Pacheco, MD (NPI: 1326187311) practices hematology/oncology in the Pueblo, CO market, with the plurality of this provider's patient population coming from Pueblo, CO. This provider's primary affiliated billing organization is ROCKY MOUNTAIN CANCER CENTERS LLP (NPI: 1518941186; TIN: 841457488) and primary practice location at 81003-9998. Pacheco is affiliated with the CommonSpirit ACO I (ACO ID: A2164) and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Pacheco's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 462 traditional Medicare patients, billed 134,338 HCPCS/CPT codes, and received $2,460,870 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,397 prescription claims across 220 beneficiaries totaling $4,525,170 in drug costs, led by Xtandi (Enzalutamide). DME data shows 45 claims. Open Payments data shows 1 records totaling $1,463. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,402,460 to $2,460,870. Similarly, Part D prescription costs have risen steadily, from $1,227,955 to $4,525,170. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	789	113,674	$1,402,460
2016	876	95,150	$1,453,481
2017	880	123,913	$1,796,314
2018	823	136,979	$1,946,059
2019	685	143,329	$2,282,073
2020	566	127,709	$2,018,401
2021	537	139,824	$2,039,759
2022	497	123,185	$2,012,890
2023	512	146,662	$2,135,648
2024	462	134,338	$2,460,870

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	185	1,263	$1,227,955
2016	197	1,316	$1,884,051
2017	208	1,434	$2,461,874
2018	214	1,393	$3,251,099
2019	221	1,189	$2,215,135
2020	166	760	$1,554,635
2021	181	885	$3,094,215
2022	188	904	$3,349,487
2023	189	1,014	$3,518,252
2024	220	1,397	$4,525,170

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	61	$4,937
2016	N/R	30	$20,243
2017	N/R	38	$17,252
2018	N/R	N/R	N/R
2019	N/R	44	$3,572
2020	N/R	29	$2,276
2021	N/R	68	$3,639
2022	N/R	54	$1,488
2023	N/R	16	$3,024
2024	N/R	45	$832

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	126	317	$103
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	124	238	$96
80053	Blood test, comprehensive group of blood chemicals	144	609	$10
36415	Insertion of needle into vein for collection of blood sample	182	691	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	166	649	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	42	1,260	$568,590
Pomalyst	Pomalidomide	22	616	$545,851
Revlimid	Lenalidomide	24	609	$475,073
Brukinsa	Zanubrutinib	29	870	$394,021
Calquence	Acalabrutinib Maleate	41	1,230	$378,915

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$362
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	19	$320
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$1,463	BeiGene USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alonso Pacheco, MD?

Tedicare shows public-source Medicare data for Alonso Pacheco, MD (NPI 1326187311), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alonso Pacheco, MD have ACO affiliation data?

Alonso Pacheco, MD is shown with ACO affiliation data for CommonSpirit ACO I (MSSP, ACO ID A2164) and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Alonso Pacheco, MD?

Alonso Pacheco, MD is linked to ROCKY MOUNTAIN CANCER CENTERS LLP (billing NPI 1518941186) in the available physician profile data.

Does Alonso Pacheco, MD have Open Payments data?

Alonso Pacheco, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.